Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Next revisionBoth sides next revision
home:starting:physician:reluctant [04.29.2019] – [Specific research] sallieqhome:starting:physician:reluctant [04.30.2019] – [Specific research] sallieq
Line 272: Line 272:
 the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})),  PMID 19124398 the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})),  PMID 19124398
  
 +Observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris.  (({{pubmed>long:20202514}}))  PMID 20202514
 +
 +This study showed that olmesartan reduces angiotensin II and aldosterone levels more effectively than azilsartan.  (({{pubmed>long:27086671}}))   PMID 27086671 
  
 improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})),  PMID 25891757 improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})),  PMID 25891757
Line 294: Line 297:
 {{section>:home:protocol:olmesartan#recent_studies_of_olmesartan_in_patients}} {{section>:home:protocol:olmesartan#recent_studies_of_olmesartan_in_patients}}
  
-{{tag>Starting_the_Marshall_Protocol letters}}+{{tag>Starting_the_Marshall_Protocol letters resources_for_physicians}}
  
 ===== Notes and comments ===== ===== Notes and comments =====
home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.